A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...

Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...

BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...

A groundbreaking study by researchers from Mass General Brigham and Washington University School of Medicine in St. Louis has ...

A scientific team looks at the progress and challenges in the research and development of brain implants. New achievements in the field of this technology are seen as a source of hope for many ...

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

In a viewpoint paper recently published in the journal The Lancet Digital Health, a team led by Stanisa Raspopovic from ...